COVID-19 vaccine efficacy data: solid enough to delay second dose?

Robertson, John F.R.; Sewell, Herb F.

doi:10.1016/s0140-6736(21)01046-1

Cited by 5 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite lower immune responsiveness, the two-dose BNT162b2 vaccine has demonstrated similar vaccine efficacy in the elderly 49 – 53 . In the early days of vaccination implementation, there was discussion on delaying the second dose in order to offer a first dose to more individuals 54 . It was recently shown that delaying the second dose provided higher immunogenicity and maintained vaccine efficacy 55 – 57 .…”

Section: Introductionmentioning

confidence: 99%

Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose

et al. 2022

View full text Add to dashboard Cite

Understanding the impact of age on vaccinations is essential for the design and delivery of vaccines against SARS-CoV-2. Here, we present findings from a comprehensive analysis of multiple compartments of the memory immune response in 312 individuals vaccinated with the BNT162b2 SARS-CoV-2 mRNA vaccine. Two vaccine doses induce high antibody and T cell responses in most individuals. However, antibody recognition of the Spike protein of the Delta and Omicron variants is less efficient than that of the ancestral Wuhan strain. Age-stratified analyses identify a group of low antibody responders where individuals ≥60 years are overrepresented. Waning of the antibody and cellular responses is observed in 30% of the vaccinees after 6 months. However, age does not influence the waning of these responses. Taken together, while individuals ≥60 years old take longer to acquire vaccine-induced immunity, they develop more sustained acquired immunity at 6 months post-vaccination. A third dose strongly boosts the low antibody responses in the older individuals against the ancestral Wuhan strain, Delta and Omicron variants.

show abstract

Section: Introductionmentioning

confidence: 99%

Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose

et al. 2022

View full text Add to dashboard Cite

show abstract

“…There are several serological testing platforms that are used to evaluate the antibody status the FDA has issued emergency authorization for ELISA, lateral flow immunoassay, and microsphere immunoassay ( 15 ). These tests measure antibodies to the SARS-CoV-2 nucleocapsid N protein or the spike protein S. Since the virus enters the cell via binding of the S protein to its cell surface receptor ACE 2 measuring antibodies to the S protein is of particular importance in preventing disease manifestation ( 16 , 17 ). A meta-analysis on serological assays for detecting antibodies against SARS-CoV-2 indicated that assays using the S antigen and testing for IgG antibodies have better sensitivity than the N antigen- and IgM-based tests ( 18 ).…”

Section: Introductionmentioning

confidence: 99%

Serological Assays for Assessing Postvaccination SARS-CoV-2 Antibody Response

Mahmoud

Ganesan²,

Naik

et al. 2021

Microbiol Spectr

View full text Add to dashboard Cite

show abstract

“…Despite lower immune responsiveness, the two-dose BNT162b2 vaccine has demonstrated similar vaccine e cacy in the elderly [10]. In the early days of vaccination implementation, there was discussion on delaying the second dose in order to offer more individuals with a rst dose [35]. In addition, it was recently shown that delaying the second dose provided higher immunogenicity and maintained vaccine e cacy [36].…”

Section: Introductionmentioning

confidence: 99%

Durable T cell responses contrast with faster antibody waning in BNT162b2-vaccinated elderly at 6 month

Rénia

Goh

Rouers

et al. 2021

Preprint

View full text Add to dashboard Cite

Efficient COVID-19 vaccines have been developed in record time. Here, we present findings from a comprehensive and integrated analysis of multiple compartments of the memory immune response in 312 individuals vaccinated with the BNT162b2 mRNA vaccine. Two vaccine doses induced high antibody and T cell responses in most individuals. However, antibody recognition of the Spike protein of delta variant was less efficient than that of the Wuhan strain. Age stratified analyses identified a group of low antibody responders where individuals ≥ 60 years were overrepresented. Waning of the antibody and cellular responses was observed in 30% of the vaccinees after six months. However, age did not influence the waning of these responses. Taken together, while individuals ≥ 60 years old took longer to acquire vaccine-induced immunity, they develop more sustained acquired immunity at six months post-vaccination. However, the higher proportion of older individuals in the group of antibody low responders and the lower antibody reactivity the Delta variant call for a booster immunization to increase immune responses and protection.

show abstract

COVID-19 vaccine efficacy data: solid enough to delay second dose?

Cited by 5 publications

References 13 publications

Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose

Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose

Serological Assays for Assessing Postvaccination SARS-CoV-2 Antibody Response

Durable T cell responses contrast with faster antibody waning in BNT162b2-vaccinated elderly at 6 month

Contact Info

Product

Resources

About